arrow
S

Stephen J. Freedland

cedars-sinai medical center
H指数:98
被引数:4.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

来自Flatiron电子健康记录数据库中化疗初治转移性去势抵抗性前列腺癌患者接受阿比特龙醋酸盐和恩扎卢amide治疗的实际世界总生存期

2026-10-120
OA
Black Race Predicts Poor Compliance and Higher Prostate Cancer Risk in a Multinational Repeat Biopsy Cohort: Secondary Analysis From the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Clinical Trial

黑人种族预示着在多次重复活检的多国队列中依从性较差且前列腺癌风险较高:来自 Dutasteride 减少前列腺癌事件(REDUCE)临床试验的二次分析

2026-09-300
PRE
Reply to Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al. re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.019

回复Francesco Barletta, Chiara Mercinelli, Francesco Montorsi等人:关于恩扎卢替胺在生化复发前列腺癌中改善生存率的文章。Eur Urol. 即将发表。http://dx.doi.org/10.1016/j.eururo.2026.01.019

2026-07-110
PRE
A WEIGHTED SCALE TO IDENTIFY EMBARK-LIKE PATIENTS AT HIGH-RISK FOR PROGRESSION AND MORTALITY AFTER BIOCHEMICAL RECURRENCE (BCR) WHO MAY BENEFIT FROM EARLY INTENSIFIED ADT

一种加权评分系统,用于识别在生化复发(BCR)后可能受益于早期强化雄激素剥夺疗法(ADT)的高风险进展和死亡率的EMBARK样患者

2026-05-010
PRE
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

使用恩扎卢胺联合醋酸亮丙瑞林治疗高风险生化复发的前列腺癌:EMBARK试验的次要终点

2026-05-016
PRE
Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?

医生记录患者前列腺特异性抗原倍增时间是否影响高风险生化复发前列腺癌的治疗决策?

2026-03-010
PRE
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort

Prostatype® P-score在多民族美国退伍军人队列中预测前列腺癌特异性死亡率的验证

2026-01-070
OAAI
Are Urologists and/or Radiation Oncologists Biased when Reporting of Advantages and Disadvantages of Surgery versus Radiation in Consultations for Early-Stage Prostate Cancer?

泌尿科医生和/或放射肿瘤科医生在咨询早期前列腺癌手术与放疗的优缺点时是否存在偏见?

2026-01-010
PRE